Cyana Therapeutics (cyanatx.com): no confident changes recorded yet; website history since July 2026. Homepage last checked 5 November 2026.
First recorded website
Observed 12 July 2026
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
How it described itself
Precision Immuno-Oncology
Cyana Therapeutics is a precision immuno-oncology company developing CY-3132, a small molecule ENPP1 inhibitor for the treatment of solid tumors. IND open, Phase 1 clinical trial planned for 2026.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
Recorded changes
Newest observations first. Each interval bounds when the website changed; it is not an exact event date.
No changes recorded yet. Missing observations do not mean the company has not changed.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
July 2026 – November 2026 · 2 captures · latest observed messagingPrecision Immuno-Oncology
Cyana Therapeutics is a precision immuno-oncology company developing CY-3132, a small molecule ENPP1 inhibitor for the treatment of solid tumors. IND open, Phase 1 clinical trial planned for 2026.